BiotechTube

Infliximab + Placebo + Naproxen

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis, Axial Spondyloarthritis

Trial Timeline

Sep 1, 2009 → Sep 1, 2011

NCT ID
NCT00844805

About Infliximab + Placebo + Naproxen

Infliximab + Placebo + Naproxen is a phase 3 stage product being developed by Merck for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00844805. Target conditions include Ankylosing Spondylitis, Axial Spondyloarthritis.

What happened to similar drugs?

20 of 20 similar drugs in Ankylosing Spondylitis were approved

Approved (20) Terminated (4) Active (0)
✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
✅GolimumabJohnson & JohnsonApproved
✅AdalimumabAbbVieApproved
✅InfliximabMerckApproved
✅GolimumabMerckApproved
✅RemicadeMerckApproved
✅RemicadeMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00844805Phase 3Completed

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
29
InfliximabCelltrionPhase 1
29
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
adalimumabEisaiPhase 3
40
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
32
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
35
Golimumab + PlaceboJohnson & JohnsonPhase 3
40
GolimumabJohnson & JohnsonApproved
43
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
38
placebo for risankizumab + risankizumabAbbViePhase 2
35
AdalimumabAbbVieApproved
39
Upadacitinib + PlaceboAbbViePhase 2
35
AdalimumabAbbViePre-clinical
26
infliximab + PlaceboMerckPhase 3
40
InfliximabMerckApproved
35
InfliximabMerckPre-clinical
26
GolimumabMerckApproved
43
RemicadeMerckApproved
43
RemicadeMerckApproved
43
InfliximabMerckApproved
43